1. Health
You can opt-out at any time. Please refer to our privacy policy for contact information.

What You Need To Know About Remicade (Infliximab)

Remicade Is A Drug Used To Treat Both Crohn's Disease And Ulcerative Colitis.


Updated July 08, 2014

Remicade (infliximab) is type of drug known as a monoclonal antibody. TNF-alpha (tumor necrosis factor alpha) is found in higher amounts in people with Crohn's disease than it is in people who do not have any form of inflammatory bowel disease (IBD). Remicade stops TNF-alpha from being used by the body.

TNF-alpha is actually a cytokine which plays a role in the inflammatory process in the body. IBD is an inflammatory condition, and TNF-alpha is believed to play a role in the way IBD affects the gastrointestinal system. A cytokine goes between cells in the body delivering chemical "messages."

How is Remicade Taken?

Remicade is given as an infusion through an IV line, often in a hospital or doctor's office setting. The infusion is given slowly over several (usually 2 more more) hours. The physician who prescribes Remicade will provide any special instructions that patients should follow before the infusion appointment.

Why is Remicade Prescribed?

Remicade may be prescribed for both of the main forms of IBD: moderate to severe ulcerative colitis or Crohn's disease. Remicade is also approved for use in children over the age of 6 who have moderate to severe Crohn's disease or moderate to severe ulcerative colitis that is not responding to other drug therapies. It may also be given for people with Crohn's disease who have fistulas and to treat certain forms of rheumatoid arthritis.

Remicade bonds to TNF-alpha, preventing it from causing inflammation in the body. With the TNF-alpha unable to cause inflammation, a person with IBD may experience an inactive time in the disease process, also called remission.

Who Should Not Take Remicade?

Tell your doctor if you have ever had any of the following conditions:
  • Allergic reactions to any medication
  • Are Currently pregnant
  • Cancer
  • Infections
  • Lupus
  • Recent vaccination

What Are the Potential Side Effects?

Common side effects of Remicade include abdominal pain, nausea, fatigue and vomiting. Tell your doctor if any side effects are bothersome or don't go away.

Rarely other, more serious side effects can occur, such as difficulty urinating, infection, irregular heartbeat and rectal pain. These side effects should be reported to your physician immediately. See the Remicade side effects page for a more complete list of potential adverse reactions.

What Medications Can Remicade Interact With?

Remicade has not been extensively studied for drug interactions. During clinical trials of Remicade, some patients were already taking antibiotics, antivirals, corticosteroids (such as prednisone), 6-MP/AZA and aminosalicylates. These patients did not experience a greater amount of infusion reactions as those who were not taking any other drugs.

Are There Any Food Interactions?

There are no known food interactions.

Is Remicade Safe During Pregnancy?

The FDA has classified Remicade as a type B drug. The effect that Remicade has on an unborn child has not been studied extensively. Remicade should only be used during pregnancy if clearly needed. Notify the prescribing doctor if you become pregnant while taking Remicade. It is not known if Remicade passes into breast milk, however other similar substances have been shown to pass into breast milk. The potential for serious side effects in an infant should be weighed against the usefulness of the medication to the mother. Another option is to discontinue breastfeeding before administering Remicade.

How Long Can Remicade Be Taken Safely?

Remicade is a newer drug -- it was approved in 1998. Therefore, no long-term information is known.

How Can I Get Help Paying for Remicade?

Centocor has a Patient Assistance Program to help in getting medical coverage for Remicade. Help may also be available from local IBD organizations.


Remicade.com. "How Remicade Works." Centocor, Inc 22 Jan 08. May 23 2008.

Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. "Infliximab for induction and maintenance therapy for ulcerative colitis." N Engl J Med 8 Dec 2005;353:2462-2476. May 23 2008.

Sands B, Anderson F, Bernstein C, Chey W, Feagan B, Fedorak R, Kamm M, Korzenik J, Lashner B, Onken J, Rachmilewitz D, Rutgeerts P, Wild G, Wolf D, Marsters P, Travers S, Blank M, van Deventer S (2004). "Infliximab maintenance therapy for fistulizing Crohn's disease." N Engl J Med 26 Feb 2004;350: 876-885. May 23 2008.

©2014 About.com. All rights reserved.

We comply with the HONcode standard
for trustworthy health
information: verify here.